Biotech voices channel feed

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

3 months ago
Coronavirus

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

4 months ago
IPOs
China

Drug dis­cov­ery in the age of coro­n­avirus

5 months ago
Coronavirus

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

9 months ago

Biotech boards bur­dened: Bridg­ing the suc­cess gap

Last year
Startups
IPOs

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

Last year
China

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

Last year
R&D
Pharma

Brad Lon­car­'s AS­CO19 pre­view: 5 big ideas to watch for at the ul­ti­mate can­cer show of the year

Last year
R&D

The right mix mat­ters in bio­phar­ma lead­er­ship

Last year

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

Last year
Deals
Pharma

Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

Last year
R&D

Phar­ma, we have a prob­lem: New drugs can't cov­er the cost of Big Phar­ma's fail­ures

Last year
R&D

May the can­dle burn for­ev­er: Po­lite re­minders about the JP­Mor­gan con­fab

Last year

Guest col­umn: The re­al cost of drug de­vel­op­ment

Last year
R&D
Pharma

Guest col­umn: The 3 big waves re­shap­ing in­vest­ment strate­gies in ear­ly-stage biotech

Last year
Venture
Startups

Brad Lon­car­'s AS­CO18 pre­view: Past AS­COs point to the top drugs that will soon el­bow for the Os­cars of can­cer R&D

3 years ago

Phar­ma's bro­ken busi­ness mod­el — Part 2: Scrap­ing the bar­rel in drug dis­cov­ery

3 years ago
R&D

Ele­phants can't jump? IDEA's Mike Rea says some Big Phar­ma play­ers are crush­ing old be­liefs

3 years ago
R&D
Special

On this Rare Dis­ease Day, let's all com­mit to help­ing rec­og­nize the life and work of biotech gi­ant Hen­ri A. Ter­meer

3 years ago

Phar­ma's bro­ken busi­ness mod­el: An in­dus­try on the brink of ter­mi­nal de­cline

3 years ago
R&D

Vi­su­al­ize: Just how much did biotech uni­corn Mod­er­na re­ly on im­mi­grants to build the staff?

3 years ago

Dear Kite: With 2300% up­side, we blazed an amaz­ing trail

3 years ago

Vi­su­al­ize: What would these 11 biotech com­pa­nies look like with­out im­mi­grants?

3 years ago
R&D
Pharma

Can­did Truths From A Biotech IPO

4 years ago
12 Next page Last page